The T cell developmental programme guides small numbers of pluripotent cells through multiple rounds of proliferation and differentiation, leading to T cell lineage commitment, T cell receptor (TCR) rearrangements, and the generation of αβTCR-or γδTCR-expressing T cells that function as killers, regulatory cells or producers of specific cytokines [1] [2] [3] [4] [5] [6] . These events are initiated and sustained by the unique thymic environment. In the past five years, the transcriptional and epigenetic mechanisms that forge T cell identity and suppress other developmental pathways have come into focus. It is not enough for cells to simply activate the set of transcription factors that maintain T cell-specific gene expression in mature T cells; instead, the developmental programme depends on the sequential operation of several distinct developmental gene networks.
In the past five years, the transcriptional and epigenetic mechanisms that forge T cell identity and suppress other developmental pathways have come into focus. It is not enough for cells to simply activate the set of transcription factors that maintain T cell-specific gene expression in mature T cells; instead, the developmental programme depends on the sequential operation of several distinct developmental gene networks.
From the time that a lymphoid precursor arrives in the mouse thymus to the first expression of an αβTCR, it traverses multiple phenotypically distinct stages that are defined by the expression of CD4, CD8 and other markers [1] [2] [3] [4] [5] [6] . These stages include FMS-like tyrosine kinase 3 (FLT3)-expressing early thymic progenitor (ETP), FLT3 − ETP, double negative 2a (DN2a), DN2b, DN3a, DN3b, transitional DN4, immature single positive (ISP) and double positive (DP), where DN refers to CD4 − CD8 − cells and DP refers to CD4 + CD8 + cells (FIG. 1a) . Most of these stages involve cell proliferation, but the degree of proliferation and the time required to reach the DP αβTCR + stage vary between lymphoid precursor cohorts. It takes a little more than a day for the first wave of lymphoid precursors that populate the fetal mouse thymus to generate DN2 cells (this occurs from embryonic day 12.5 (E12.5) to E14) and only a total of 4 days for the first DP cells to appear (at E16). By contrast, the lymphoid precursors that continuously trickle into the thymus throughout young adult life can take 10 days to reach the DN2 stage and 2 weeks to develop into DP cells, with the extra time providing the opportunity for much more extensive proliferation 7, 8 . Despite these kinetic differences, the gene expression patterns that occur at given stages of fetal and adult thymocyte development are similar 9 . This similarity extends to the transcription factor genes that are characteristically expressed at each stage (FIG. 1b) , as well as to the differentiation genes that these factors regulate. Thus, the transcriptional control of proliferation and developmental progression is, to some extent, modular and may depend on checkpoints to ensure orderly differentiation. Distinct phases of T cell development are controlled not only by the presence of key transcription factors but also by the coordination between such transcription factors, which is mediated by gene regulatory network connections.
All of the events that establish the T cell identity of precursors are driven by Notch signalling [10] [11] [12] [13] . Notch 1 molecules on the surface of lymphoid precursors interact with Notch ligands in the thymic microenvironment, leading to activation of the T cell-specific developmental programme. During the first developmental stages, Notch signalling interacts with a 'legacy' stem and progenitor cell gene network that is 'inherited' from
Commitment
The stage at which cells give up their intrinsic capability to produce more than one kind of descendant. This concept depends on recognizing that precursor cells begin with the intrinsic potential to give rise to various different types of descendant, but the actual fate choices that such precursor cells adopt will be different depending on the signals that they receive from the environment. Commitment is the developmental transition within a given pathway during which the chosen cell fate becomes intrinsically irreversible, independent of the environment.
Gene regulatory network
A system of relationships between a set of regulatory genes and the transcription factors that they encode, which is defined such that the interactions between them explain the stability or change in the developmental properties of a cell type that expresses those genes. multipotent precursors. As described in detail below, legacy genes that will have ongoing roles in T cells and also progenitor-specific legacy genes with roles confined to the earliest stages of T cell development participate in this network, which we term 'phase 1' (FIG. 1b) . Although it is still incompletely understood, the phase 1 network may support the extensive proliferative expansion of the ETPs and DN2a cells, as well as influence the order, timing and level of T cell gene activation. Notch signalling also activates the first T cell lineage-specific transcription factors by interacting with the phase 1 network, although the newly induced factors only exhibit full T cell specification activity under the continuing influence of Notch signals as cells shift to the 'phase 2' network.
T cell-specific transcription factors in the phase 2 network mediate commitment-linked functions that drive T cell-specific gene expression, open the TCR gene loci for rearrangement and repress the expression of the progenitor cell-specific phase 1 genes. The phase 2 network thus creates the distinctive T cell identity. However, this phase 2 network must also be substantially modified once TCR gene rearrangement occurs and enables some cells to express either a pre-TCR (TCRβ with invariant pre-Tα) or a γδTCR. The resulting TCR signal transduction (under the influence of Notch signalling) triggers another shift in the gene regulatory network, transitioning into 'phase 3' . The phase 3 network includes newly activated genes Nature Reviews | Immunology
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Notch signalling
A signalling system comprised of highly conserved transmembrane receptors that regulate cell fate choice in the development of many cell lineages and are thus crucial for the regulation of embryonic differentiation and development. Unusually among signalling systems, the cytoplasmic domain of each Notch transmembrane protein can itself become a transcriptional co-activator in the nucleus, as it can be proteolytically cleaved from the transmembrane region when Notch interacts with its ligands of the Delta or Jagged family.
that support the T cell phenotype but also leads to the extinction of expression of some factors that had crucial roles in phase 2, decreasing Notch target gene expression and enabling the cells to become Notch independent.
The switching between the three phases must be correctly regulated to ensure the fidelity of T cell development and to avoid leukaemogenesis. The activation of new regulatory genes and the repression of those from earlier phases must be accurately coordinated to ensure proper passage through the developmental checkpoints. An important question is how homogeneous the precise trajectory of gene expression changes may be between the surface receptor-defined stages of T cell development and this will require future studies using single-cell transcriptional analysis 14 . However, a strong relationship has recently emerged between the generation of T cell leukaemias and the inappropriate persistence of gene expression from the phase 1-restricted network of normal T cell development, which is associated with thymocyte precursor self-renewal [15] [16] [17] [18] [19] . This relationship provides insights into the origins of certain forms of human T cell acute lymphoblastic leukaemia (T-ALL), as well as suggesting roles for specific stem and progenitor cell genes in the regulatory networks that are involved in normal T cell development.
Thus, a three-phase succession of gene networks drives the development of multipotent precursors into cells that are committed to the T cell lineage and sets them on the path to developing distinct functional roles. The expression of certain transcription factors can extend across the boundaries of these phases but their functions in each phase are modulated according to their expression level and to the overall state of the gene network. In this Review, we explore what these functions are and how they are interlinked.
Major features of early T cell development
Progenitor interaction with the thymic environment. T cell progenitors from the bone marrow or fetal liver continuously seed the thymus via the blood. The major types of pre-thymic cells that seem to be competent to do this are multipotent precursors -primarily common lymphoid precursors (CLPs), which express high levels of interleukin-7 receptor (IL-7R) and low levels of the receptor tyrosine kinase KIT (also known as SCFR and CD117), and lymphoid-primed multipotent precursors, which have lower IL-7R expression but express high levels of KIT [20] [21] [22] [23] . Although the respective in vivo contributions of these precursors remain to be elucidated, once in the thymus, the ETPs that are derived from them share a KIT hi IL-7R low phenotype and develop into KIT hi IL-7R hi DN2a cells before T cell lineage commitment. In fact, both of these growth factor receptors (KIT and IL-7R) are crucial for the proliferative expansion of early pro-T cells within the thymus. Both types of thymic immigrant also express the functionally important growth factor receptor FLT3, as well as Notch 1 (REF. 24 ). The unique thymic environment not only provides supportive cytokinessuch as KIT ligand and IL-7 -that maintain and expand the precursors, but it also crucially provides an environ ment that is rich in the Notch ligand Delta-like ligand 4 (DLL4) 6 . Engagement of cell-surface Notch 1 by environmental Notch ligands triggers the proteolytic release of intracellular Notch 1, which binds to DNA-bound recombining binding protein suppressor of hairless (RBPJ; also known as CSL) and recruits a transcriptional co-activator complex to stimulate the expression of Notch target genes 25 .
Stages of early T cell development. The process of differentiation from thymic entry to the expression of a full heterodimeric TCR can be roughly divided into Notchdependent and TCR-dependent parts (FIG. 1a) . The early cells do not express a TCR, and they proliferate and differentiate in a TCR-independent, Notch-dependent manner. As soon as TCR gene rearrangement yields its first successful products, cell survival and differentiation become TCR dependent, and the influence of Notch is , which comprises essentially all of the T cell progenitor activity, and this is the only type of DN1 cell that is considered further here. Key cell-surface receptors that are used to identify these stages of T cell development are shown, indicating the stages at which each receptor is expressed. Striped lines indicate stages with lower expression levels. Development is divided by the commitment and β-selection checkpoints into three major regulatory phases that each have unique gene networks and cellular characteristics. Cells in phase 1 proliferate extensively and retain multipotentiality, whereas phase 2 cells are committed to the T cell lineage, slow their proliferation and undergo T cell receptor (TCR) rearrangements. Only cells with a rearranged TCRβ that can combine with pre-Tα to form the pre-TCR and transduce a signal can continue through the β-selection checkpoint into phase 3, which is a second highly proliferative -but increasingly Notch-independent -phase that leads to the upregulation of CD4 and CD8 expression, then proliferative arrest and TCRα rearrangement. b | Stage-specific patterns of expression of important transcription factor genes are shown. The colour intensity variation provides an approximation of the dynamic changes in expression of the genes, which are grouped together on the basis of similar expression patterns although not necessarily similar expression levels. For a more accurate quantitation of gene expression, see the sources of the data that are presented in this figure (Zhang et al. 31 and ImmGen 32, 194 ). The transcription factor genes are divided into legacy stem and progenitor cell genes that are mostly turned off in phase 1 and are all off by β-selection (shown in blue), and genes that are crucial to different aspects of the T cell specification and commitment programmes (shown in red). Additional information about each of these genes is provided in 
.
A major landmark in the Notch-dependent developmental process is T cell lineage commitment, which occurs at the DN2a to DN2b transition (FIG. 1a) . Commitment marks the final loss of factors and gene regulatory networks that would potentially enable alternative lineage choices under permissive conditions 4, 26 
. Under normal conditions in the thymus, Notch ligands instruct and retain progenitor cells in the T cell pathway -in an environment that blocks alternative fate choices -but during commitment, the accumulation of Notch-dependent gene regulatory changes makes these alternative fates inaccessible regardless of the environment. The transition to a committed phenotype was originally detected using an Lck-GFP transgene 27 and is marked in non-transgenic animals by a subtle decrease in KIT expression 1, 28 . In fact, however, this transition involves a major change in gene regulation, which causes both the substantial upregulation of many T cell genes and the loss of progenitor-specific gene expression. Dendritic cell, myeloid cell, NK cell, innate lymphoid cell subset 1 (ILC1), and probably ILC2 and mast cell potentials are all terminated here 4, 26, 29, 30 (FIG. 2) . Thus, the Notch-dependent period of T cell development is divided into two phases -pre-commitment (phase 1) and T cell lineage identity (phase 2) -which are distinct in their transcription factor gene network states and developmental properties (FIG. 1b) .
By the time commitment has occurred (DN2b-DN3a stage), the expression of most T cell identity genes is fully turned on 31, 32 . Such genes include all of the in variant TCR components and mediators of TCRdependent signalling, the expression of which prepares the cells for TCR-dependent survival. Proliferation slows as cells progress to the DN3a stage and many cells enter G1 arrest. At this stage, cells persist until they successfully rearrange their TCR genes or they die. Growth and differentiation beyond the β-selection checkpoint at DN3a normally requires the expression of a functional TCR, which activates the phase 3 gene network. This occurs when newly made TCRβ protein assembles at the cell membrane with TCR complex components that are already expressed, including pre-Tα (encoded by Ptcra), CD3γ (encoded by Cd3g), CD3δ, CD3ε (encoded by Cd3e) and TCRζ. The assembly of this pre-TCR complex triggers cell enlargement, progression into rapid cell cycling, termination of CD25 (encoded by Il2ra) expression and increased surface expression of CD27 (also known as TNFRSF7) and the co-stimulatory molecule CD28, as the cells enter DN3b and then DN4 and ISP stages [33] [34] [35] [36] [37] . Although Notch signals are required for passage through the β-selection checkpoint [38] [39] [40] , cells that are able to signal through the pre-TCR then free themselves from their Notch dependence and turn off expression of Notch target genes. A somewhat different pathway is followed by cells that productively rearrange the genes encoding TCRγ and TCRδ in the DN2-DN3 stages -these become one of a variety of γδTCR + cell types
. These cells also transition from Notch-dependent to Notch-independent differentiation at this point.
Key members of T cell regulatory networks
The expression of T cell differentiation genes and many aspects of mature T cell function eventually depend on a toolkit of transcription factors that includes T cell factor 1 (TCF1; encoded by Tcf7) and its relative lymphoid enhancer-binding factor 1 (LEF1), GATA-binding protein 3 (GATA3), B cell lymphomaleukaemia 11B (BCL11B), E2A (encoded by Tcf3), HEB (encoded by Tcf12), Ikaros (encoded by Ikzf1) or family members, MYB, growth factor-independent protein 1 (GFI1), and complexes of Runt-related transcription factor 1 (RUNX1) or its family members with core-binding factor-β (CBFβ) (as reviewed in REFS 3, 4, [41] [42] [43] [44] [45] [46] [47] (TABLE 1 ). The process of T cell programming, through phase 2 and beyond, must establish gene networks that stably maintain appropriate expression levels of these factors. However, these are only part of a much larger set of transcription factors that are differentially regulated during the T cell specification process 31, [48] [49] [50] (FIG. 1b; TABLE 1 ).
Box 1 | γδ T cell development
Two classes of T cells expressing distinct T cell receptor (TCR) dimers, αβ and γδ, have been maintained in all jawed vertebrate taxa since TCR-expressing cells first evolved 169 . γδ and αβ T cells have a common intrathymic precursor but they follow different differentiation programmes following TCR expression 170 . The successful assembly of a γδTCR triggers signals that lead to the downregulation of CD25; however, γδTCR + cells proliferate much less than pre-TCR + cells (which are destined to become αβTCR + cells) and do not turn on expression of CD4 or CD8. Specific characteristics of individual precursor cells at different stages may bias them towards the γδ or αβ T cell lineage. Double-negative 2 (DN2) cells in general, particularly those with high levels of expression of interleukin-7 receptor (IL-7R) and/or SOX13, can generate γδ T cells at a high frequency, but individual DN3a cells are more likely to produce αβ T cells 38, [171] [172] [173] ( FIG. 2) . The interplay of Notch signals with signals from the newly expressed pre-TCR or γδTCR is important for αβ versus γδ T cell divergence 38, 40 , although the outcome of this interaction differs between mice and humans 174 . A γδTCR can produce a stronger signal than a pre-TCR, leading to greater upregulation of Id3 (which encodes inhibitor of DNA binding 3) and Egr (early growth response) family factors, and the initiation of a γδ rather than an αβ T cell programme 175, 176 . Interestingly, γδTCR signalling triggers one of several different genetic programmes for maturation of γδTCR-expressing cells, which depend differentially on Id3, Sox13, Zbtb16 (also known as Plzf) and/or Bcl11b (which encodes B cell lymphoma-leukaemia 11B) for further development and effector functions 126, 128, 172, [177] [178] [179] . The range of accessible γδ-subtype fates narrows with differentiation from DN2a to DN3a 128 . These γδ T cell lineage-specific programmes mirror the range of T helper 1 (T H 1), T H 2, T H 17 and natural killer T cell effector programmes that αβ T cells acquire at later stages, either after positive selection or in the periphery. However, γδ T cells can implement specific effector programmes directly when they first express and signal through the TCR within the thymus. Unlike αβ T cells, these functions in γδ T cells correlate with particular TCRγ and TCRδ segment usages 177 (as reviewed in REFS 170,180,181).
Positive selection
A step in the process of T cell differentiation in the thymus that selects CD4 + CD8 + double-positive T cells for survival and maturation, on the basis of the appropriate degree of interaction between their T cell receptor and the peptide-MHC complexes that are expressed on thymic epithelial cells. Depending on the class of MHC molecule that is recognized, thymocytes are positively selected to a CD4 + or a CD8 + single-positive cell fate.
The induction of crucial T cell specification genessuch as Tcf7, Gata3 and Bcl11b -by thymic Notch ligands occurs in the context of previously established legacy stem and progenitor cell transcriptional networks. These legacy networks are not immediately dismantled and many of these progenitor-specific factors persist through multiple cell cycles and developmental stages within the thymus (FIG. 1) , even though continued expression of these regulatory genes beyond the ETP and DN2a stages may be oncogenic. Furthermore, some of these progenitor genes are now known to have important roles during the pre-commitment phase, as described below. Understanding how these phase 1-restricted factors contribute to normal T cell development and leukaemia is an important research frontier.
The phase 1 T cell regulatory network Phase 1-restricted transcription factors. Because the development of each T cell precursor cohort is coupled with proliferation, the steady-state percentage of thymocytes that are in pre-commitment stages is tiny. However, in these early stages, TCR-independent proliferation of any given thymic immigrant can be extensive, spanning more than ten cell cycles before commitment 7, 51 , and this proliferative expansion could be a major function that is supported by the legacy progenitor cell gene network. Many of the transcription factors that are expressed only in phase 1 ETPs and/or DN2a cells have roles in the proliferation, survival and self-renewal of other haematopoietic cells and can be involved in the pathogenesis of leukaemias, as the genes that encode them are functionally implicated as proto-oncogenes (see below and TABLE 2).
From thymic entry to commitment, the cells progress through several variants of the phase 1 regulatory state, resulting from the staggered loss of expression of legacy phase 1-restricted genes and the gain of Notch target gene expression (FIGs 1b,3a-c). The most restricted subset of phase 1 regulators -including the transcription factors that are encoded by Gata2, Meis1 (which encodes Meis homeobox 1) and Hoxa9 (which encodes homeobox A9) -is expressed solely or predominantly in ETPs. Some of these genes may be co-expressed with Flt3 in a pattern that is restricted to the most primitive ETPs, as these genes are known to be involved in regulatory networks in FLT3 + pre-thymic progenitors 52, 53 . The possible functions of these genes in pre-thymic progenitors are intriguing but they are probably important for supporting engraftment in the thymus. The expression of Mef2c (which encodes myocyte enhancer factor 2C) and Lmo2 (which encodes LIM domain only 2) is turned off a little later. These can persist into the DN2a stage, particularly in adult thymocytes, which have a prolonged period of expansion 31, 32 . The phase 1 factors LMO2, MEIS1 and NMYC (encoded by Mycn; see below) have a direct connection to 'stem-ness'; they have recently been identified as potent components of a transcription factor 'cocktail' that can reprogramme differentiated blood cells back into haematopoietic stem cells 54 .
The most characteristic group of phase 1-restricted transcription factors is expressed throughout the precommitment stages. These include Spi1 (which encodes PU.1; also known as Sfpi1), Hhex (which encodes haemato poietically expressed homeobox protein), Bcl11a, Gfi1b (which encodes growth factor-independent protein 1B), Erg and Lyl1 (which encodes lymphoblastic
Box 2 | Mechanisms of alternative lineage exclusion
Common lymphoid precursors (CLPs) and lymphoid-primed multipotent precursors (LMPPs) retain the potential to generate diverse lymphocyte types, as well as natural killer (NK), dendritic and myeloid cells, under different permissive conditions [21] [22] [23] 52 . However, contact with the thymic environment efficiently blocks the access of CLPs and LMPPs to these non-T cell lineages through various mechanisms. Thus, under normal conditions, the overwhelming majority of thymic precursors only generate T cells in situ 182, 183 . Nevertheless, a gene network state providing latent competence to switch to other non-T cell fates persists throughout the first few stages of T cell development and can be detected by experimentally removing the cells from the normal thymus. Alternative lineage potentials are lost at different times (FIG. 2) and by at least three different mechanisms. At the earliest thymic stage, as early thymic progenitors (ETPs) turn off expression of Flt3 (which encodes FMS-like tyrosine kinase 3), they unconditionally lose their B cell potential 21, 24, 99, 184 . The mechanism by which this occurs is dependent on Notch signals and GATA-binding protein 3 (GATA3) 24, 97 but remains incompletely defined 21, 99, 184 . The exclusion of myeloid and dendritic cell potentials is caused by the removal of a positive regulator. Access to both options correlates with the expression profile of PU.1 and, at early stages, CCAAT/enhancer-binding (C/EBP) factors -which are present at low levels -may also contribute 185, 186 . While PU.1 is present, Notch signalling keeps myeloid options under check. First, Notch-induced HES1 represses Cebpa (which encodes C/EBPα) 75 . Notch signalling also modulates the spectrum of PU.1 transcriptional activities irrespective of C/EBPα 66, 185, 187 . PU.1 is silenced during the DN2b stage, under the influence of Runt-related transcription factor 1 (RUNX1) and possibly also T cell factor 1 (TCF1) or GATA3 (REFS 29, (188) (189) (190) , which closes off the myeloid options.
The loss of access to NK cell and innate lymphoid cell subset 2 (ILC2) fates may instead be due to activation of the repressor Bcl11b (which encodes B cell lymphoma-leukaemia 11B). Both NK cell and ILC2 programmes require inhibitor of DNA binding 2 (ID2) in order to neutralize E protein activity, and BCL11B is directly implicated in keeping Id2 silent 117, 118, 122 . Ironically, essential T cell lineage regulatory inputs may themselves lead to alternative lineage diversion during the uncommitted stages of T cell development if their levels are dysregulated. The overexpression of Gata3 can drive the cells towards a mast cell fate 29 by antagonizing Notch-dependent survival systems. GATA3 and TCF1 can also function in a state of low E protein activity to promote the development of ILC2s 30, 191, 192 instead of T cells, and excessive Notch signals may favour ILC fates in human precursors 193 . Access to these alternative fates is blocked during the commitment transition by mechanisms that remain to be clarified. leukaemia 1) (FIG. 1b; TABLE 2 ). The Lyl1 relative Tal1 (which encodes T-ALL protein 1; also known as SCL) is also in this group but is expressed at much lower levels than Lyl1. Most of these genes are repressed partially or completely during the transition to phase 2 (between DN2a and DN2b), although the expression of Lyl1 is only silenced in the DN3a stage 28 and that of Erg and Mycn only during β-selection 31, 32 . BCL11A is crucial for normal lymphoid pro genitor proliferative expansion in both fetal liver and bone marrow 55 . Similarly, although the basic helix-loop-helix (bHLH) factor LYL1 is best known for its role in haematopoietic progenitors and B cells 56, 57 , deletion of Lyl1 severely impairs the development of lymphoid precursors in the bone marrow and specifically decreases the proliferative expansion of ETPs, progression to the DN2 stage and early T cell survival 56, 58, 59 . Similar to the function of the related protein TAL1, LYL1 -which forms dimers with E2A or HEB -probably helps to maintain the expression of the crucial ETP-DN2 growth factor receptor KIT and promotes the expression of Gfi1, which is a regulatory factor that is required for the normal generation of ETPs and for proper responses to Notch signalling 58, 60, 61 . ERG and HHEX are implicated in early T cell self-renewal in both normal and malignant contexts 62, 63 . Thus, despite their transient expression, these factors should be regarded as integral parts of the T cell lineage developmental programme.
PU.1: linking phase 1 and developmental options.
PU.1 is normally associated with the differentiation of non-T cells (dendritic, myeloid and B cells) 64 and its expression strongly correlates with the ability of un committed T cell precursors to divert to dendritic cell and myeloid cell fates when Notch signalling is withdrawn (FIG. 2) . However, the loss of PU.1 from the pre-thymic or DN1 stage also causes an arrest in T cell development 65 . PU.1 is important for the expression of FLT3 by thymic immigrants and it probably sustains the pro-survival functions of BCL11A in developing thymocytes until Nature Reviews | Immunology 
Pioneer factor
A transcription factor that has the ability to bind to its target site even when the site is initially located within nucleosome-packed chromatin, thus serving as a focal point for the recruitment of other transcription factors. Pioneer factors are crucial for the multi-step process that is needed to activate some positive regulatory elements in the genome during development.
they reach commitment (phase 2), as well as regulating other phase 1 genes 66 . PU.1 is a highly stable protein and can function as a pioneer factor in some contexts [67] [68] [69] [70] . It binds to most enhancers and promoters that are active in ETPs and DN2a cells in vivo 31 . Thus, it may (in part) shape the epigenetic landscape in these haematopoietic progenitors in ways that affect the activities of many other factors. It may also have a more direct role in controlling the T cell programme via network interactions with Notch and T cell commitment genes, including Tcf7, Myb and Gata3 (REF. 66 ). PU.1 can dampen the intensity of Notch signalling and this contributes to its ability to restrain the induction of many T cell identity genes for as long as it is expressed 66 (A. Champhekar and E.V.R., unpublished observations). Because this Notch antagonism is graded and not absolute, PU.1 may contribute to the proliferative expansion of T cell precursor clones by delaying the onset of commitment, as described below.
Notch target genes in early T cell precursors. Notch signalling activates distinct target genes in disparate developmental contexts and, even in DN thymocytes, it activates a succession of different target genes at different stages. DN thymocytes are primed for responsiveness to intrathymic Delta ligands by their expression of Fringe proteins that are encoded by Lfng, Mfng and Rfng 71 . Notch signalling tightly controls the expression of genes encoding the canonical DN2 marker CD25, the ubiquitylation adaptor Deltex1 (encoded by Dtx1), pre-Tα, Notch-related ankyrin repeat-containing protein (NRARP), Notch 3 and, to some extent, Notch 1 itself, as well as the transcription factors MYC and HES1, all of which have different patterns of expression in the DN thymocyte stages 39, 72, 73 . Notch signalling also strictly controls the activation of a distinct promoter for Tcf12 that drives the expression of a truncated HEB protein, known as alternative HEB 
T-ALL
Gfi1
• SNAG • C2H2-like ZnF
Partial block between ETP and DN2 stages Potentiates T-ALL AML, acute myeloid leukaemia; B-ALL, B cell acute lymphoblastic leukaemia; Bcl11b, B cell lymphoma-leukaemia 11B; bHLH, basic helix-loop-helix; C2H2, a form of zinc finger (Cys 2 His 2 ); DN, double negative; DP, double positive; ETP, early thymic progenitor; ETS, E26 transformation-specific; Gata3, GATA-binding protein 3; Gfi1, growth factor-independent protein 1; HEBCan, canonical full-length HEB protein; HMG, high-mobility group; HSC, haematopoietic stem cell; HTH, helix-turn-helix; ISP, immature single positive; Lef1, lymphoid enhancer-binding factor 1; NK, natural killer; Runx1, Runt-related transcription factor 1; SNAG, Snail/Gfi1 domain (a repression domain); T-ALL, T cell acute lymphoblastic leukaemia; TCF1, T cell factor 1; ZnF, zinc finger. *For a fully referenced version of Table 1, see Supplementary Information S1 (table) .
(HEBAlt), which seems to be more supportive of cell proliferation than canonical full-length HEB protein (HEBCan) or E2A 46, 74 . However, many of these genes are not activated immediately in ETPs.
Hes1 and Nrarp are among the earliest Notchactivated target genes to be induced in ETPs. HES1 is a bHLH transcriptional repressor that is required for early T cell population expansion and it may also antagonize myeloid cell development [75] [76] [77] . NRARP is an adaptor protein that can function as a negative feedback regulator of Notch signalling itself 78, 79 . Whereas Hes1 expression continues from the ETP stage through to the DN3a stage, Nrarp expression is shut off at the time of T cell lineage commitment. Thus, in phase 1, Notch signalling is self-limiting and exacerbates the Notch responsedampening effect of PU.1. Both restraints are relieved, however, when the cells undergo commitment. The later-activated Notch target genes may thus be dependent on an increase in Notch signal strength for their induction, as well as on other inputs.
Building infrastructure for the phase 2 network
The regulatory bridge to the phase 2 gene network is built from within the phase 1 network. Notch signalling in ETPs initiates the expression of the crucial regulatory genes Gata3 and Tcf7 (which encodes TCF1), which then alter the developmental status of the cells (FIG. 3a,b) . Even in the context of the phase 1 developmental network, these two genes begin to promote T cell-lineage commitment as soon as they are expressed, as knockout of either gene markedly decreases the survival and differentiation of ETPs, as well as their descendants 80, 81 . GATA3 and TCF1 not only begin to antagonize the progenitorspecific, phase 1-restricted factors (FIG. 3b) , but they also collaborate with the regulatory factors required for T cell development that were part of the legacy set that was inherited from a pre-thymic stage (for example, MYB, RUNX1, CBFβ, Ikaros, GFI1 and E2A). A particularly important member of this group of inherited factors is the bHLH factor E2A. Although E2A is expressed at relatively constant levels throughout T cell specification, its activity is substantially modulated by the availability of different heterodimerization partners 45, 46, 58, [82] [83] [84] [85] [86] . Despite their stable expression, all of these progenitor-inherited factors can also function in developmentally modulated ways, and they become incorporated with TCF1 and GATA3 into the network for T cell lineage commitment.
Activation and function of TCF1.
Tcf7 is activated by Notch directly 81, 87 but once activated, its expression is no longer markedly affected by Notch signal inhibition 29, 66 . This indicates that its expression may become self-sustaining by direct or indirect positive feedback (FIG. 3c) . In ETPs, TCF1 drives the expression of a suite of genes that are required for survival and proliferative expansion 81 . Some fetal T cells can develop without it 88, 89 but TCF1 becomes increasingly important in postnatal waves of T cell precursors 90 . TCF1 primarily functions as a crucial positive regulator of T cell specification, collaborating with Notch to activate T cell genes through a feedforward network circuit. Although TCF1 cannot duplicate all of the effects of Notch signalling, forced expression of high levels of a full-length isoform of TCF1 can activate the expression of many T cell genes including Gata3, Bcl11b, Il2ra, Cd3g, Lat (which encodes linker for activation of T cells), Lck and endogenous Tcf7 in the responding cells, even without Notch signals 87 . It is still controversial whether TCF1 functions together with β-catenin in these positive regulatory roles 87, 91 . Although it can mediate canonical WNT signalling via the formation of a complex with β-catenin, TCF1 may operate in a different manner in ETPs and DN2a cells. At a later stage of T cell development, TCF1 can directly or indirectly help to repress the expression of inhibitor of DNA binding 2 (ID2), a potent E2A antagonist that can otherwise be induced readily in T cell precursors 89 . Certain natural isoforms of TCF1 also repress or delay activation of the related gene, Lef1, which can otherwise become oncogenic 88, 89 . Finally, as a highly abundant transcription factor in developing T cells, TCF1 may also have an architectural role at cisregulatory elements across the genome 92 , as its highmobility group DNA-binding domain can bend the DNA to facilitate contacts between other DNA-bound transcription factors 93 . In pre-thymic cells, the gene encoding TCF1 (Tcf7) has substantial CpG methylation on some of its putative regulatory elements 94 but its promoter and major enhancer become fully active during the ETP stage 31 , and CpG methylation is removed from Tcf7 by the time cells reach the DN2 and DN3 stages 94 . This may reflect the activity of Notch-RBPJ complexes at the enhancer, in addition to direct and indirect positive feedback signals from TCF1 and GATA3 (REFS 81, 87) . Initially, Notch signalling remains important to maintain Tcf7 expression in the context of a variety of experimental regulatory perturbations, ranging from excessive PU.1 activity 66 to excessive GATA3 activity 29 . However, in the later stages of T cell development (phase 3 and beyond), Tcf7 can be strongly expressed in a Notch-independent manner and this is often correlated with levels of GATA3.
GATA3 function and regulation. GATA3 has crucial dose-dependent roles in early T cell survival, growth, specification and commitment, as well as continuing roles in T cell subset diversification after TCR expression and antigen stimulation 95, 96 . It has a key non-redundant role in excluding the B cell fate 97 , which probably explains why B cell potential is lost within the ETP stage 24, 98, 99 . GATA3 is required to fully activate Bcl11b expression in DN2a-DN2b cells and to prime DN3 cells for β-selection, and it may also upregulate Ets1 and repress Spi1 (PU.1) expression in DN2b cells 29, 97, 100 (D. D. Scripture-Adams, S. Damle and E.V.R., unpublished observations) (FIG. 3c-e) . Gata3 expression is activated by a mechanism that involves a far downstream enhancer 101 and by the removal of H3K27me3 repression marks from its promoter 102, 103 , although the sequence (or sequences) through which it is activated by Notch in ETPs has not been identified. Part of the regulation of Gata3 could be mediated indirectly -for example, by TCF1. Although GATA3 levels can be maintained when Notch signals are removed, Notch signalling is required to enable Gata3 to be expressed in the context of high PU.1 activity during phase 1 (REF. 66 ).
GATA3 must be tightly regulated at several levels. First, the negative effects of Gata3 overexpression on T cell development are as severe as the loss of this transcription factor 29, 104 . In the pre-commitment stages, Gata3 expression can be restrained by the phase 1 transcription factors PU.1 and GFI1B 66, 105 (FIG. 3a,b ).
During and after commitment, Gata3 expression is restrained by other T cell specification regulators including E2A and BCL11B 104 (J. A. Zhang, L. Li and E.V.R., unpublished observations) (FIG. 3d,e) . Second, GATA3 is subject to considerable post-transcriptional regulation by signalling pathways that are downstream of many growth factor and activation signals, including AKT pathway-mediated regulation of Gata3 translation and p38 mitogen-activated protein kinase (MAPK)-mediated regulation of GATA3 nuclear localization and activity [106] [107] [108] . Thus, the levels of GATA3 activity in a cell integrate responses to environmental signals with intrinsic transcriptional programming. Third, the sites that GATA3 binds across the genome are distinct at different stages of T cell development, even for stages with equivalent levels of GATA3 expression. Major redistributions of GATA3 binding are seen between successive DN and DP thymocyte stages, as well as between thymocytes and mature T cells 31, 109 . This is not because GATA3 is particularly excluded by repressed (H3K27me3-marked) chromatin sites but is because of shifting preferences between potential open sites. The implication is that GATA3 'assignments' depend on interactions with changing stage-dependent collaborating factors. Thus, as a member of a regulatory ensemble, GATA3 may contribute in different ways to each of the three phases that cells pass through from the ETP stage to the DP stage.
Phase 2: commitment Transition to phase 2. Several cell cycles after TCF1 and GATA3 are expressed, cells transition to the DN2b stage, when proliferation rates slow, survival becomes strictly Notch dependent and KIT expression decreases 28 . During this stage, Bcl11b expression is activated and most phase 1 genes are silenced (FIG. 3c,d) . As the cells progress through the DN2b stage, there are major shifts in the expression of ETS family transcription factor genes; Ets1 and Ets2 are rapidly turned on and Spi1 is turned off 48 . Lef1 is induced in a highly Notch-dependent manner 29, 66 , providing a function that is partially redundant with that of its relative Tcf7 (REFS 88,89,110 ).
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Bcl11b Bcl11b B cell lymphoma-leukaemia 11B (encoded by Bcl11b). Note that E2A-HEB heterodimers can have a positive role in the induction of Gata3 (which encodes GATA-binding protein 3) and Tcf7 (which encodes T cell factor 1 (TCF1)), as well as restraining the maximum levels of Gata3 expression. The expression of T cell receptor (TCR) recombination and assembly genes markedly increases from the double-negative 2a (DN2a) to the DN3a stage (panels c-e) but these genes are most functionally significant in DN3a cells. As revealed by phenotypes of T cell acute lymphoblastic leukaemia (T-ALL), cells that take a 'short cut' from the states represented in panels a and b to the activation events in panel f (thus bypassing the commitment process) are susceptible to oncogenic transformation. "HEB" indicates the composite effects of the canonical full-length HEB protein (all panels) and the alternative short-form HEB protein (panels c-e). "Notch" indicates the composite effects of Notch 1 (all stages) and Notch 3 (in panels d and e). DLL4, Delta-like ligand 4; Gfi1b, growth factor-independent protein 1B; Hhex, haematopoietically expressed homeobox protein; Hoxa9, homeobox A9; Ikzf1, gene encoding Ikaros; Lef1, lymphoid enhancer-binding factor 1; Lmo2, LIM domain only 2; Lyl1, lymphoblastic leukaemia 1; Mef2c, myocyte enhancer factor 2C; Meis1, Meis homeobox 1; Runx1, Runt-related transcription factor 1; Spi1, gene encoding PU.1; Tal1, gene encoding T-ALL protein 1 (also known as SCL).
Chromatin immunoprecipitation followed by sequencing (ChIP-seq). A genome-wide method of mapping the sites at which a transcription factor binds to the DNA in a cell, that involves crosslinking proteins to chromatin, immunoprecipitating the chromatin with antibodies specific for the factor of interest, comprehensively sequencing the DNA that is recovered in the immunoprecipitates and aligning the obtained sequences with the genome to identify the enriched regions.
During in vitro differentiation, DN2b cells can continue to proliferate, but in vivo, all of these changes presage a faster shift to the DN3a stage. The cells become desensitized to IL-7R signalling in a process that is dependent on E proteins 111 . The activity of E2A and HEB is probably boosted by the silenced expression of the competitive binding partner LYL1 (REFS 28, 112) . E protein-dependent and Notch-dependent gene expression markedly increasesfor example, the expression of recombination activating gene 1 (Rag1), Rag2, Ptcra, terminal deoxynucleotidyltransferase (Dntt) and Cd3e 72, 83, 104, [113] [114] [115] -and as proliferation slows, RAG-mediated TCR gene recombination intensifies (FIG. 3e) .
Bcl11b expression is necessary for many, if not all, of these changes and the timing of Bcl11b activation is crucial for lineage commitment [116] [117] [118] . The expression of BCL11B, a six zinc-finger transcription factor with functions including co-repressor activity 119 , is turned on in late DN2a cells. It may repress Kit expression directly, thus creating the DN2b phenotype; almost all DN2b cells express high levels of Bcl11b (H. Y. Kueh and E.V.R., unpublished observations). Both the promoter and a far-distant enhancer seem to participate in Bcl11b activation and they contain binding sites for RBPJ, TCF1, RUNX1-CBFβ and possibly GATA3 (REF. 120 ), all of which are positive regulators of Bcl11b expression 87, 97, 118, 121 . These known positive regulators are expressed before Bcl11b is turned on but their combined levels may need to exceed a threshold in order to remove initial DNA methylation and H3K27me3 marks from both the promoter and the enhancer of the Bcl11b gene 94, 120 . Commitment: end of progenitor status and other options. The commitment transition from DN2a to DN2b marks the end of a process of excluding cells from potential access to alternative fates (FIG. 2) . The completion of T cell lineage commitment in the DN2b stage terminates access to 'innate lymphocyte' (NK cell, ILC1 or ILC2) development 28, 30 and, perhaps surprisingly, the potential for accessing non-lymphoid pathwayssuch as the development of dendritic cells, granulocytes, macro phages and possibly mast cells -is also extinguished only at this point (as reviewed in REF. 26 ). At least three kinds of molecular mechanisms implement different aspects of alternative lineage exclusion, including the repression of Spi1 (PU.1)
The silencing of Spi1 has an obvious link to T cell lineage commitment, but commitment also silences many other phase 1 factors such as Gfi1b, Hhex, Bcl11a, Lmo2 and Mef2c, which have less clear roles in promoting alternative cell fates. Even in some leukaemias that show aberrant expression of these factors (see below), they immortalize pro-T cells without obscuring their T cell lineage identity. This implies that T cell commitment excludes a progenitor-like form of self-renewal, as well as specific alternative differentiated fates. Commitment mechanisms that silence phase 1 genes are thus most likely to underlie the alteration in the control of cell growth that intensifies Notch dependence, slows proliferation and finally brings proliferation under strict TCR dependence 28 .
The phase 1-specific regulatory genes that are silenced after DN2a show diverse repression patterns. The levels of positive enhancer and promoter marks -H3K4me2 and H3K(9/14)ac -on these genes are reduced as transcription decreases but H3K27me3 repression marks generally only begin to appear later (if at all), often not until the DP stage 31, 103 . BCL11B is required for silencing other phase 1 genes during commitment, including Lyl1, Hhex, Bcl11a and possibly Spi1 but it is not yet clear whether BCL11B acts directly on them as a repressor (J. A. Zhang, L. Li and E.V.R., unpublished observations) [116] [117] [118] 122 . Thus, various negative regulatory mechanisms ensure that phase 1 proto-oncogenes are silent by the time that cells reach the β-selection checkpoint. (FIG. 3e) . Chromatin immunoprecipitation followed by sequencing (ChIP-seq) analysis has shown that GATA3 binding is redeployed in DN3a cells from its phase 1 network gene targets to a new set of target genes 31 . Some transcription factors, including aryl hydrocarbon receptor (encoded by Ahr) and SPIB, are transiently expressed only during this DN3a stage (FIG. 1b) but their functions at this point are unknown. The maximal expression of the Cd3 gene cluster is regulated by E proteins, GATA3 and TCF1; the Rag genes are induced by E proteins and GATA3; and Hes1, Notch3 and Ptcra are jointly regulated by E proteins and Notch 31, 83, 104, 114, 123 . The involvement of E proteins is a hallmark of gene expression in DN3a cells in particular, and E proteins, Notch signalling and BCL11B may have a particularly tight collaboration. E proteins are required to promote and sustain Notch 1 expression in DN3a cells and Notch signalling can be antagonized by the E protein antagonist ID2 (REFS 66, 124) . BCL11B may thus support the DN3a state by keeping Id2 expression silent 117, 118, 122 (FIG. 3d,e) .
A change in the potential for cells to become αβ versus γδ T cells between the DN2 and DN3a stages could also be related to their differential needs for BCL11B and Notch signalling, as well as the strong activation of ID3 or ID2 factors that is linked to selection of most γδ T cell lineages 125 . The Notch and E protein target gene Ptcra is very poorly activated in Bcl11b -/-cells. Accordingly, αβ T cells are disproportionately affected by Bcl11b deletion 126, 127 , whereas several γδ T cell lineages -particularly fetal lineages and those that emerge early from the DN2 stageare much less affected 117, 122, 126, 128 . Thus, special features of the DN3a stage may set up the conditions for selection processes that are specific to the αβ T cell lineage.
Phase 3: crossing the β-selection checkpoint Construction of the checkpoint. The proliferation and differentiation checkpoint that is imposed at DN3a is enforced by E2A and Ikaros 84, 129, 130 . There are several clues from target gene analyses that indicate why proliferation might stop at this point. E2A may slow cell cycling by inducing the expression of Cdkn1a 114 (which encodes cyclin-dependent kinase inhibitor 2A), which is co-expressed with Cdkn2d. Other features of the cells indicate that they are progressively starved of growth signals. As they lose support from IL-7R signalling, the cells upregulate expression of the inhibitory phosphoinositide 3-kinase-interacting protein 1 (PIK3IP1) and the growth-suppressive death-associated kinase 1 (DAPK1) in response to E2A 104 , and these may make the cells dependent on the ever-stronger viability signals from Notch and eventually from the pre-TCR 131 . Although Ikaros is stably expressed from the earliest stages of T cell development, it also has a crucial dose-dependent role in enforcing the β-selection checkpoint 130, 132 . The complexes that Ikaros forms are pivotal for the deployment of nucleosome remodelling activity across the genome 133 . It is still unclear exactly how Ikaros contributes to cell cycle arrest and TCR gene rearrangement but it is known to strongly and rapidly suppress Notch target genes after pre-TCR signals are received [134] [135] [136] , and this is crucial for blocking leukaemogenesis.
β-selection. Signalling through the newly expressed pre-TCR and passage through the β-selection checkpoint disrupt the quiescence of DN3a-stage αβ T cell precursors. The expression of both Notch target genes and Il7r is shut off as cells move to the DN3b stage and beyond 34 (FIGS 1,3f) .
Despite the downregulation of these growth-supporting systems, the cells enter a period of very rapid proliferation, as they become highly responsive to chemokine signalling through CXC-chemokine receptor 4 (CXCR4) 137, 138 . Proliferation not only expands the potential TCR repertoire pool but also helps αβ T cells to confirm their lineage commitment by enabling the cells to dilute out the last vestiges of earlier regulatory molecules and to reset epigenetic marks 37 .
Creating the new DP state, the expression of Ets1, Tcf7, Lef1, Ets2 and Tcf12 (specifically canonical HEB) further increases. The expression of several new transcription factors is turned on during β-selection. These include retinoic acid receptor-related orphan receptor-γt (RORγt; encoded by Rorc), nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 3 (encoded by Nfatc3), POU6F1 and Aiolos (encoded by Ikzf3), which are stably activated. Other transcription factors, such as early growth response protein 2 (EGR2) and ID3, are transiently activated in response to the TCR signal during the rapidly proliferating DN4 stage (FIG. 1) . Although E protein activity is transiently antagonized by this temporary increase in ID3 expression, E protein dominance is subsequently restored 139 . RORγt expression in thymocytes is highly specific to DP cells, where it functions in a different gene network context to that found in mature T H 17 cells 140, 141 . In DP cells, RORγt works with MYB to promote cell viability through the induction of Bclxl (also known as Bcl2l1), while suppressing conventional effector responses such as proliferation and cytokine production [142] [143] [144] . The roles of TCF1 and LEF1 may be qualitatively altered at this point by a stage-specific interaction with the canonical WNT pathway mediator β-catenin, which is more strongly implicated in the effects of WNT signalling at β-selection than at earlier stages 88, [145] [146] [147] [148] . This altered regulatory factor ensemble turns on the expression of the genes encoding CD4, CD8, CD2 (in mice) and CD28.
Arguably, the most dramatic feature of the change in the developmental gene network at β-selection is repression. Any residual expression of phase 1 genes vanishes, together with that of DN3-specific regulatory genes such as Spib, Ahr and the Notch-dependent genes. The whole Notch-dependent regulatory framework is dismantled like a redundant assembly scaffold (FIG. 3f) . The broad downregulation of multiple Notch target genes may result from the repression of Lfng, which prevents Notch on DP cells from accessing its intrathymic ligands 71 . As cells become DP, H3K27me3 repression marks accumulate at the promoters of phase 1 genes and Notch target genes such as Hes1 (REFS 31, 103) . The resulting new regulatory state prepares DP thymocytes for the complex positive and negative selection events that they must undergo.
Although relatively few 'new' factors enter the regulatory mix at this stage, the β-selection cascade is dangerous because of the way in which new growth signals impinge on a rapidly changing regulatory state. Cells with inadequate E protein or Ikaros activity cannot control access to this transition or re-establish quiescence correctly and they can become malignantly transformed. Notch target genes must be silenced, as inappropriately prolonged Notch activity -in the context of TCR complex activation during β-selection -pushes the cells towards leukaemic transformation. Furthermore, as described below, any persistence of phase 1 gene expression during this transition stage can itself lead to leukaemia.
T cell leukaemia
Checkpoint failure and T cell leukaemias. The earliest stages of T cell development are replete with potent protooncogenes (FIG. 1b; TABLE 2 ) that are inherited from prethymic progenitors. Many of these genes encode factors that regulate proliferation, survival and differentiation in the earliest stages of T cell development, in conjunction with the Notch-mediated T cell specification programme, but the termination of this progenitor programme is imperative both for completing T cell specification and for avoiding leukaemogenesis. The overexpression of individual phase 1 transcription factors in mouse haematopoietic stem and progenitor cells commonly leads to self-renewal and transformation, with the specific leukaemia type depending on the cell subset in which the transcription factor is first overexpressed (TABLE 2) . In addition, recent data show that if early thymic cells are not displaced from their intrathymic niches by new immigrants, they retain self-renewal potential and thus the threat of leukaemic transformation persists [15] [16] [17] . The repression of legacy proto-oncogenes occurs at several developmental points (FIG. 1) . Whereas the expression of a subset of these genes is terminated within the ETP stage, others are expressed through to the commitment checkpoint, after which time most of these phase 1-specific genes are repressed. By the time cells transit through the β-selection checkpoint, remnants of the stem and progenitor cell programme are fully and permanently extinguished. Epigenetic mechanisms probably have important roles in establishing and maintaining repression of the progenitor cell gene programmes, although the process needs clarification and it is likely that it varies between stages and specific genes. For example, progenitor cell genes that continue to be expressed until commitment are generally not strongly marked by H3K27me3 until after β-selection, even though most are repressed from the DN2 stage 31 . These results indicate that proliferation might be needed for the establishment of repressive chromatin.
T-ALLs in humans are a heterogeneous group of aggressive T cell malignancies that are thought to arise from the oncogenic transformation of immature thymocytes 149 . These leukaemias can result from the mutation and/or uncontrolled activation of a T cell proto-oncogene -such as Notch -or from the translocation of an exogenous oncogene to T cell specific promoters or enhancers -such as those of a TCR locus or BCL11B. Subtypes of human T-ALL, with different treatment responses and relapse rates, have been identified on the basis of the surface phenotype and genetic signature of T cells, including their overexpression of specific transcription factors and surface receptors that are characteristic of different stages of the T cell differentiation programme [150] [151] [152] [153] [154] . Although these genetic signatures provide clues about the primary and cooperating genetic lesions in the multi-step process that drives malignant transformation, manipulable mouse models are invaluable for investigating the sequential genetic lesions that can initiate and sustain T-ALLs. Some markers of T cell development differ between humans and mice 155, 156 but the broader requirements for Notch and cytokines, as well as the underlying transcriptional networks, are very similar 157 , such that the results from studies in mouse models are relevant to human T-ALL.
The failure to transit correctly through the β-selection checkpoint due to sustained Notch signalling or the loss of E proteins or Ikaros has long been known to result in the malignant transformation of early T cells 132, [158] [159] [160] . Constitutively activated Notch signalling is particularly potent at triggering T cell leukaemia in both humans and mice, with more than 50% of human T-ALL cases having activating mutations in NOTCH1 or its signalling pathway 149, 158, 161 . However, in both mice and humans, distinct 'early' subtypes of T-ALL exist that are characterized by very immature T cells and these may arise from a failure to permanently repress phase 1 stem and progenitor cell legacy genes, which have only recently been recognized to have a major involvement in early T cell differentiation 154 . High levels of expression of the phase 1 genes LYL1 and LMO2 were originally found to distinguish subtypes of human T-ALL that are associated with higher rates of treatment failure and relapse 151 . Subsequently, a T-ALL subtype was designated as ETP T-ALL (ETP-ALL) on the basis of the overexpression of genes that are known to be expressed by mouse ETPs, including KIT, GATA2, CEBPA (which encodes CCAAT/enhancer-binding protein-α), SPI1, LYL1 and ERG 1, 18 . ETP-ALL cells also express myeloid surface markers and have lower levels of expression of typical T cell genes than other types of T-ALL. Genome-wide sequencing of human ETP-ALL cells showed that they commonly have activating mutations in cytokine receptor genes (FLT3 or IL7R) and genes encoding components of RAS signalling pathways, as well as inactivating mutations in some important T cell genes and specific histone-modifying genes 19 . These cells have a greater resemblance to myeloid stem cells and acute myeloid leukaemia cells than to other forms of T-ALL 19 . Thus, the genetic characteristics of ETP-ALLincluding the genes that are shared with myeloid progenitors -indicate a failure to properly terminate the normal phase 1 regulatory state, despite the onset of the T cell specification programme. As in mouse early T cells, the human T cell development programme could emerge from an immature myeloid-like precursor state 162 . Specific genes that are involved in epigenetic silencing are mutated in many cases of ETP-ALL, in particular EZH2, SUZ12 and EED
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, which are part of the polycomb repressive complex 2 (PRC2) that mediates H3K27 trimethylation. This further supports a role for these pathways in extinguishing the expression of phase 1 stem and progenitor cell genes during normal commitment, as has been indicated by repression marking patterns in mice 31 . However, loss-of-function mutations in components of PRC2 are also found in other types of T-ALL, which indicates that PRC2 has more diverse stage-specific roles in normal T cell development and tumour suppression 163 . Other genes that encode proteins involved in establishing gene repression, such as the DNA methyltransferase 3A (encoded by DNMT3A), are also mutated in some subsets of T-ALL 164 , although the role of this gene and of other epigenetic factors in early T cell development and leukaemia initiation in mice and humans is yet to be determined.
Three mouse models have provided additional insights into the mechanisms of leukaemogenesis that occurs as a result of the loss of phase 1-specific transcription factor gene repression. First, when it is overexpressed in mouse DN thymocytes, the ETP-specific gene Lmo2 generates a self-renewing population of KIT hi DN thymocytes and the mice develop T cell leukaemias after a long latency period 63, 165 . Although the frank leukaemia probably depends on accumulating additional mutations, the preleukaemic self-renewing cells already express other phase 1 genes -including Hhex and Lyl1 -which have cooperative roles with Lmo2 in self-renewal and leukaemogenesis 59, 63 . Although most cases of T-ALL also have activating mutations in the Notch pathway, it is noteworthy that this is much less frequent in ETP-ALLs. T cell lineage-restricted expression of an Lmo2 transgene induces T-ALL in mice by two distinct pathways; one pathway requires Notch activation but the other ETP-ALL type requires only the sustained expression of classic phase 1 genes, such as Lmo2, Lyl1, Hhex and Mycn
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Second, early T cells from Cdkn2a
−/− mice could be transformed by retroviral transduction with an Il7r gene carrying constitutively activating mutations that were identified from human cases of ETP-ALL. The cells generated transplantable leukaemias resembling human ETP-ALL 166 , in which myeloid cell potential was combined with an early T cell phenotype. These mutations blocked cell differentiation at an uncommitted DN2a-like stage. The leukaemic cells had high levels of Lmo2 expression and low to undetectable levels of Bcl11b expression, and most did not have activating Notch mutations. This mouse model shows that abnormal cytokine receptor signalling can prevent or reverse Lmo2 silencing, Bcl11b upregulation and T cell lineage commitment, and that this can efficiently lead to transformation.
Third, RAG1-deficient non-obese diabetic mice (NOD mice) exhibit a spontaneous emergence of an aberrant self-renewing thymocyte population from the DN2 stage. These mice develop highly penetrant T cell leukaemias that share some gene expression features with human ETP-ALL 167, 168 . The abnormal thymocytes emerge from the DN2 stage as KIT hi cells that fail to repress many of the phase 1-specific genes, including Lmo2, Lyl1, Hhex and Mef2c. These emerging cells also continue to follow some aspects of the T cell programme by activating genes that are characteristic of committed DN3 cells, such as Ptcra and Spib. However, they bypass the β-selection checkpoint even without TCR gene rearrangements and aberrantly turn on expression of Cd4, Cd8 and Cd5. Thus, this model provides additional evidence that a failure to repress the stem and progenitor cell gene programme at the commitment checkpoint can initiate T cell trans formation. Furthermore, transformation at this checkpoint does not necessarily preclude the aberrant activation of some aspects of the T cell differentiation programme.
Taken together, these studies of mouse and human T-ALL indicate that a breakdown of repressive mechanisms that are normally enforced at the commitment and β-selection checkpoints can lead to specific forms of T-ALL. A more complete understanding of the epigenetic and checkpoint control mechanisms in normal T cell development may shed light on leukaemia initiation and the subsequent transformational events that lead to the generation of leukaemia stem cells.
Conclusions
The T cell commitment programme is not a simple cumulative progression towards the assignment of T cell character, but rather it is a series of distinct regulatory phases with different and sometimes mutually antagonistic features (FIG. 3) . An initial phase of proliferative expansion during which differentiation is actively deferred is important to establish an adequate pool of cells and it is this phase 1 developmental programme that is 'tuned' to promote varying numbers of cell divisions according to the needs of fetal and postnatal T cell development. At least some of the stem and progenitor cell factors that are required to sustain this phase are incompatible with T cell lineage commitment and their expression must be repressed. A lasting feature of the commitment process is the irreversible silencing of phase 1 factors. The commitment process establishes a growth-limited state that is dominated by different transcription factors, at least one of which, BCL11B, is only expressed at the time of commitment. Other features (such as intensified Notch signalling) are normally temporary, lasting until cells acquire a pre-TCR or γδTCR, which enables them to exit the commitment process and pass into a third phase. The effective termination of each phase as the cells transition to the next can be viewed as a crucial defence against malignant transformation. A failure to terminate the phase 2 programme as the cells pass through β-selection -by continuing Notch activity -has long been recognized to contribute to T-ALL. It is now clear that particularly severe forms of T-ALL are those in which the phase 1-2 transition is porous or too easily recrossed. Thus, the early lineage commitment events that occur in only a tiny fraction of cells in the steady-state thymus at any given time not only offer an illuminating paradigm for developmental fate determination but also have extreme significance for the fate of the organism as a whole.
